Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details
Effect of Beta-blocker Discontinuation on Functional Capacity and Cardiac Hemodynamics in Patients with Heart Failure with Preserved Ejection Fraction
Clinical Trial ( IRB ) #: 22-145-2
Title: Effect of Beta-blocker Discontinuation on Functional Capacity and Cardiac Hemodynamics in Patients with Heart Failure with Preserved Ejection Fraction
Principal Investigator: Dr. Kai Chen
Description: Heart failure (HF) is a growing public health problem associated with significant mortality and healthcare cost. Heart failure (HF) can be classified into two distinct types based on cardiac muscle contractility measured as ejection fraction - HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Significant advances in the HF therapy over the past decades have substantially improved the outcome in patients with HFrEF. In contrast, there is no effective therapy available for HFpEF, which remains to be the ";single largest unmet need in cardiovascular medicine";1. Beta-blocker (BB) - The survival benefit of BB in treating HFrEF 3, but not HFpEF, has been well established. Despite of lacking evidence, BB use was shown in 80% of HFpEF patients enrolled in both TOPCAT and PARAGON-HF trials4,5, and in 66% of HFpEF patients in our observational study excluding atrial fibrillation and CAD. This pilot study is to evaluate the effect of beta-blocker withdrawal on functional capacity and cardiac hemodynamics in patients with HFpEF.
Classification:
  Cardiovascular (Heart, High Blood Pressure, Etc.)
Eligibility Criteria: Check with study contact
How to Contact: Sharon DiMauro. Telephone: (860) 679-2692. Email: dimauro@uchc.edu
Enrollment Status/Comments: Enrolling/recruiting. For current recruitment status, please check with study contact.